Trending Health cover logo

Obesity Drug Market: Opportunities and Obstacles

20m · Trending Health · 14 Mar 13:07

The obesity drug market has grown dramatically in the last few years, especially with the help of social media and influencers. The immense popularity of anti-obesity medications has transformed a health industry development into a cultural phenomenon. While this market has so much opportunity, it also faces supply issues and coverage gaps. Mindy and Jen are joined by Vynamic’s Head of Life Sciences, Karen Baldry, and Head of Health Plans, Saurabh Raman, to talk about the growth and challenges obesity medications present for the health industry.

Podcast Tags: healthcare, obesity, weight loss, diabetes, health services, health plans, life sciences

Source Links:

  • What Is Ozempic and Why Is It Getting So Much Attention?
  • We Know Where New Weight Loss Drugs Came From, but Not Why They Work
  • What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know
  • Supply Updates about Wegovy
  • The increase in appetite for obesity drugs
  • Demand for GLP-1 drugs is growing. Here\’s why payers are hesitant to cover them for weight loss
  • More than 4,000 ads for Ozempic-style drugs found running on Instagram and Facebook
  • Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs
  • Medicare is barred from paying for weight-loss drugs like Wegovy. Lawmakers just took the first step to change that
  • Cost isn’t the only reason Medicare doesn’t cover Wegovy
  • New marketing push by Ozempic and others sparks body-positive backlash
  • What You Need to Know About Compounded Versions of Popular Weight Loss Drugs
  • Novo antes up $16.5B to poach CDMO giant Catalent amid Wegovy surge
  • Wegovy, other GLP-1s could lower heart disease: Study
  • Novo kidney trial finds Ozempic cuts cardiac deaths in diabetics
  • How Ozempic and Weight Loss Drugs Are Reshaping Denmark’s Economy
  • Novo Nordisk\’s Wegovy bonanza looms large in Denmark
  • Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion
  • Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect
  • Ozempic vs Wegovy
  • Obesity drug boom pushes Novo Nordisk shares to record high
  • Popular use of obesity drugs like Ozempic could change consumer habits

Panel – Jen Burke, Mindy McGrath, Karen Baldry, Saurabh Raman

Research & Production – Adrea Cope, Everly Petruzzelli

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

The episode Obesity Drug Market: Opportunities and Obstacles from the podcast Trending Health has a duration of 20:26. It was first published 14 Mar 13:07. The cover art and the content belong to their respective owners.

More episodes from Trending Health

NHS’s Cybersecurity Problem, A Win for Psilocybin Research

In this Trending News Europe episode, Jack, Jen, and Ollie discuss a few recent newsworthy items, including an increase in cyberattacks on the healthcare sector, Europe’s plan to future-proof its Biotech Sector and New Research from the University of Oxford into psilocybin as a potential treatment for depression.

Podcast Tags: healthcare, healthcare news, life sciences, NHS, cybersecurity, biotech, research & development, pharmaceuticals, depression, psilocybin, mental health, psychedelics, mental health awareness week

Source Links:

  • ’Large volume’ of data stolen from NHS Dumfries and Galloway published on dark web
  • Huge volume of NHS patient and staff data released by hacker
  • NHS cyber attack: Why stolen medical information is so much more valuable than financial data
  • Cyber attacks are one of the biggest threats facing healthcare systems
  • Government Launches NHS Cyber Security Strategy
  • US tech group Palantir wins lucrative NHS data contract
  • Patient privacy fears as US spy tech firm Palantir wins £330m NHS contract
  • European Commission lays down path to future-proof EU biotechnology
  • Roche to buy Carmot for up to $3.1bn as race for obesity drugs intensifies
  • Roche agrees $7.1bn deal for Telavant to boost drug pipeline
  • Europe’s biotech innovation in the balance
  • Commission takes action to boost biotechnology and biomanufacturing in the EU
  • Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
  • EU launches landmark €6.5M study on use of psychedelics to treat mental disorders
  • Magic mushrooms’ psilocybin can alleviate severe depression when used with therapy
  • Psychedelic drug research held back by UK rules and attitudes, say scientists
  • King’s College Psychoactive Trials Group

Panel – Jack Young, Jen Burke, Ollie May

Research & Production – Karan Pandya, Jack Young

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

The Benefits of Early Launch Planning

As competitive and regulatory pressures increase, Life Sciences organizations are tightening their timelines and budgets when bringing products to market. In this environment, it’s become essential to start commercialization planning earlier to ensure a successful launch and hit revenue targets. In this deep dive episode, Jen is joined by Vynamic’s Product Launch Service Leads, Ashley Stanley and Brian Stamm, as well as Managing Director of PROPENSITY4, Chris Savage, to discuss why early planning is so critical and how leaders can incorporate some of these changes into their organizations.

To learn more about Vynamic’s work in Product Launch, visit Vynamic’s Product Launch page. To read more on navigating alliance product launches, see Vynamic’s latest insight here.

PROPENSITY4, part of Inizio Engage, is transforming pharmaceutical commercialization through seamless integration of data, expertise and cutting-edge analytics. See more about what PROPENSITY4 can do for your team at Data and Integrated Insights | Inizio Engage.

Podcast Tags: healthcare, life sciences, product launch, healthcare news, life sciences trends, product launch trends

Source Links:

  • Product launch challenges and how to overcome them
  • Drug launches reflect overall company performance
  • TO SPEND OR NOT TO SPEND: Investing For Launch Success As An Emerging Company
  • Revenue of the worldwide pharmaceutical market from 2001 to 2023
  • Prices for new US drugs rose 35% in 2023, more than the previous year
  • Next in pharma 2024: Reinventing for returns
  • The Unbearable Cost of Drug Development
  • Understanding the Factors that Impact the Pre-Launch Phase and New Product Launch Excellence in the Pharmaceutical Industry
  • FDA Approves Many New Drugs in 2023 that Will Benefit Patients and Consumers

Panel – Jen Burke, Ashley Stanley, Chris Savage, Brian Stamm

Research & Production – Adrea Cope & Everly Petruzzelli

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Trending News US – May 2, 2024

In this episode, Mindy, Ryan, and Jen discuss recent newsworthy items, including the FDA approval of Rejoyn, the first prescription digital treatment for major depressive disorder. They also discuss the ongoing drug shortage crisis, as well as changes coming out of the Centers for Medicare & Medicaid Services and the impact those decisions will have over the next year.

Podcast Tags: healthcare, healthcare news, life sciences, health policy, public health, depression, mental health, digital treatment, drugs, pharmaceuticals, shortages, medications, FDA, CMS, Medicare Advantage, breakthrough technology, medical devices

Source Links:

  • FDA clears first digital treatment for depression, but experts caution that research is still early
  • Number of ongoing US drug shortages reaches new high, pharmacist group says
  • FDA commissioner tells lawmakers his agency needs more authority to prevent drug shortages
  • CMS final rule on broker comp, health equity could shake up Medicare Advantage
  • Medicare official says breakthrough device reimbursement rule coming in early summer

Panel – Jen Burke, Mindy McGrath, Ryan Hummel

Research & Production – Anna Briccetti, Jen Burke

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

From Ambition to Action: AI in the Health Industry

While the health industry is not always an early adopter of new technologies, the growth of generative artificial intelligence (GenAI) has empowered organizations to start transforming their AI aspirations into actions. In this episode, Mindy and Jen are joined by Vynamic’s Innovation Lead, Michael Hudson, and Responsible AI Lead, Todd Quartiere, to discuss where we see health organizations experimenting with AI and what it will take for them to achieve their long-term AI ambitions.

To learn more about implementing AI within your organization, check out our recent insight: Why AI fails or flourishes: The underestimated role of culture.

Podcast Tags: health, healthcare, healthcare news, generative AI, innovation, responsible use, ChatGPT

Source Links:

  • The Unexpected Winners of the ChatGPT Generative AI Revolution
  • Generative AI in healthcare: Emerging use for care
  • US healthcare leadership: How to respond and thrive
  • How Can AI Improve Health Care?
  • Envisioning Healthcare in a Post-COVID-19 World
  • Three-quarters of health professionals project widespread AI adoption
  • 5 Key Healthcare Industry Trends to Watch in 2024
  • What Do We Mean When We Talk About “AI Democratisation”?

Panel – Jen Burke, Michael Hudson, Mindy McGrath, Todd Quartiere

Research & Production – Danielle Lewis, Jen Burke

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Trending News Europe – 18 April 2024

In this Trending News Europe episode, Jack, Jen, and Ollie discuss recent newsworthy items from across Europe, including the impact of and deterrents against “no shows” at medical appointments, therole bacteria play in cancer treatment, and inequalities in the rare disease market, along with the steps being taken to ease these issues.

Podcast Tags: healthcare, healthcare news, life sciences, public health, France, medical, bacteria, cancer, immunotherapy, chemotherapy, microbiome, rare disease, Germany, Italy, health disparity

Source Links:

  • Dutch hospitals use AI to solve no-show patient problems that cost them millions
  • Cancellations of NHS care are having serious impacts on two-thirds of patients
  • Would charging patients for missed appointments help fund the NHS?
  • GP \’no shows\’ cost Norfolk NHS more than 1m in a one month
  • France planning €5 no-show fees in a bid to improve community healthcare
  • France divided over ‘no-show tax’ for patients failing medical appointments
  • Researchers compile detailed catalog of bacteria living in cancer metastases
  • Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech
  • The key to young onset bowel cancer may be gut bacteria
  • The mystery of microbes that live inside tumours
  • Diversity of Bacteria in Cancer Metastases
  • It’s the Little Things: A Role for Bacteria in Cancer Treatment
  • The UK is missing out on EU collaboration to improve treatment for rare diseases
  • Overcoming the burden of rare diseases in Europe
  • Stronger together in the fight against rare diseases
  • Is Europe on track to be the leader in rare diseases?
  • Right here, right now European public health policies must start giving people living with rare diseases a fair chance
  • New rare diseases action plan on horizon, Europe at turning point
  • Europe needs new 360 rare diseases strategy

Panel – Jack Young, Jen Burke, Ollie May

Research & Production – Karan Pandya

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Every Podcast » Trending Health » Obesity Drug Market: Opportunities and Obstacles